Maintenance friendly Foundayo pharmacies
Reaching your goal weight is where the next problem starts: many providers stop prescribing once your BMI drops below the licence thresholds. This directory tracks the UK pharmacies that support continued Foundayo treatment at lower BMIs, under clinical supervision.
Pharmacies supporting Foundayo maintenance
Every provider listed here has passed our manual verification checks, including certificates, and has confirmed a maintenance prescribing policy. Listings are randomised on each page load so no provider holds a fixed position.
Foundayo was authorised by the MHRA on 10 August 2026 and UK pharmacies are still establishing their prescribing and maintenance policies for it. We are contacting providers directly to confirm their maintenance criteria, and no pharmacy will appear here until it has passed verification and confirmed its policy in writing. In the meantime, our maintenance guide covers what to expect, and Monj's Mounjaro maintenance directory shows how the same checks look once populated.
What the figures mean
BMI information is based on details provided by each pharmacy. Prescribing is always a clinical decision, so approval is never guaranteed and may vary by patient.
- Lowest joining BMI
- The lowest BMI at which a provider may accept you when switching from another pharmacy.
- Lowest maintenance BMI
- The lowest BMI at which a pharmacy may continue prescribing to help you maintain your weight under clinical supervision.
- Time limited
- Whether a provider caps how long it will prescribe for, for example up to two years.
Trust, methodology and fair display
How we vet: we independently verify GPhC registration and certificates manually, then confirm ongoing prescribing policies directly with clinical teams. Providers we cannot reach, or whose policy we cannot confirm, are excluded rather than guessed at.
Fair display: this list reorders on every page load so exposure is shared. No provider can pay for a fixed position, a badge or favourable wording. Dayo may earn commission from tracked links, which never affects inclusion or order; see our independence statement and pricing methodology.
Review cadence: maintenance policies, BMI thresholds and prices are reviewed regularly, and each listing carries the date it was last confirmed. Policies change often, so always confirm current criteria with the provider before switching.
Last reviewed: 23 August 2026
Why maintenance pharmacies are a separate problem
Foundayo's UK licence covers adults with a BMI of 30 or above, or 27 to 30 with a weight-related condition.1 Those thresholds are written for starting treatment. The awkward consequence is that successful treatment moves you out of them: lose enough weight and you may fall below the BMI at which your provider is willing to keep prescribing.
That is not a loophole, it is a genuine clinical judgement call, and providers differ in how they handle it. Some will continue at a reduced dose with monitoring, some will taper you off, and some stop at a fixed threshold. Since stopping GLP-1 treatment without a plan is typically followed by substantial regain, knowing your provider's policy before you reach goal weight matters more than most people realise.
What to ask before you need the answer
- What is your lowest maintenance BMI? The number at which they will stop prescribing.
- Do you support dose tapering? Finding the lowest effective dose is both cheaper and often clinically preferable.
- Is there a time limit? Some providers cap total treatment duration regardless of BMI.
- What monitoring is included? Long-term treatment should involve real reviews, not an automated repeat.
- What happens if I want to stop? Cancellation terms and tapering support vary widely.
If you are already close to your goal and your current provider will not continue, switching is straightforward but needs timing: see our switching pharmacy guide for how to move without a treatment gap.
Maintenance options a provider may offer
- Continue at the same dose where clinically appropriate.
- Reduce to a lower maintenance dose on the six-step ladder.
- Taper gradually and stop, with monitoring afterwards.
- Stop and monitor weight without medication.
- Switch treatment entirely, which is where the ATTAIN-MAINTAIN evidence on moving from injectables to tablets becomes relevant.2
Plans are tailored rather than fixed, and the right one depends on your weight history, treatment response and overall health. Our maintenance guide covers the clinical side in full, and stopping Foundayo covers the honest picture on regain.
Be wary of "no BMI limit" marketing
A provider willing to prescribe a weight-management medicine at any BMI, with no clinical rationale, is not being generous: they are being careless, and possibly unlawful. Foundayo is prescription only and must be prescribed against a genuine clinical assessment.1 Low maintenance thresholds should always come with monitoring and a documented rationale. Our red flags guide covers what careless looks like.
Sources and references
- MHRA: UK first in Europe to authorise orforglipron for weight management and type 2 diabetes — licensed BMI thresholds and prescription-only status
- ATTAIN-MAINTAIN trial — maintenance of weight loss after switching from injectable GLP-1 treatment to orforglipron
- General Pharmaceutical Council register of pharmacies — verifying every listed dispensing pharmacy
- NICE — UK guidance on managing obesity as a long-term condition
Reviewed against primary sources. See our editorial policy for how we source and update content.